FBT has surged 232.6% over the past five years and is the top-performing non-leveraged ETF since the start of the current bull market in March 2009. [Celebrating the Bull Market With ETFs]
None of the ETF’s holdings account for more than 5.35% of the fund’s weight. FBT has long been one of the epicenters of biotech mergers and acquisitions activity. Along with Pharmacyclics (NasdaqGS: PCYC), which is being acquired by AbbVie (NYSE: ABBV), several of FBT’s holdings have been rumored to be potential targets. Pharmacyclics is FBT’s second-largest holding at a weight of 5.2%. [More M&A Lifts Biotech ETFs]
First Trust NYSE Arca Biotechnology Index Fund
